Entry Point Capital, LLC Igm Biosciences, Inc. Transaction History
Entry Point Capital, LLC
- $112 Billion
- Q1 2024
A detailed history of Entry Point Capital, LLC transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 15,801 shares of IGMS stock, worth $194,826. This represents 0.14% of its overall portfolio holdings.
Number of Shares
15,801Holding current value
$194,826% of portfolio
0.14%Shares
1 transactions
Others Institutions Holding IGMS
# of Institutions
89Shares Held
20.5MCall Options Held
11.1KPut Options Held
5.1K-
Baker Bros. Advisors LP New York, NY4.09MShares$50.4 Million0.5% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.89MShares$47.9 Million0.0% of portfolio
-
Artal Group S.A. Luxembourg, N43.08MShares$38 Million1.6% of portfolio
-
Redmile Group, LLC San Francisco, CA3.07MShares$37.9 Million1.17% of portfolio
-
Goldman Sachs Group Inc New York, NY1.28MShares$15.8 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $357M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...